E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 12/19/2014 in the Prospect News Convertibles Daily.

Convertibles Calendar

On The Horizon

INOTEK PHARMACEUTICALS CORP.:

• Convertible senior notes

• Maturity 2019

• Concurrent initial public offering of common stock

• Registered

• Non-callable for life

• Takeover and dividend protection

• Joint bookrunners Cowen & Co. LLC, Piper Jaffray & Co., Canaccord Genuity Inc. and Nomura Securities International Inc.

• Proceeds to fund the continued development of its pharmaceutical candidates and for other general corporate purposes, including repayment of borrowings under and the termination of existing notes payable agreements

• Beverly, Mass.-based development stage pharmaceutical company

• Proposed Nasdaq listing: ITEK

CARNIVAL GROUP INTERNATIONAL HOLDING LTD.:

• Unsecured senior convertible bonds

• Bookrunner Deutsche Bank AG, Hong Kong Branch

• Regulation S

• Concurrent equity swap with Deutsche Bank AG, London Branch as equity swap counterparty

• Proceeds to fund existing and new projects; entry into the equity swap; and for working capital and other general corporate purposes

• Bermuda-based investment holding company engaged in leisure and consumption businesses

• Hong Kong: 00996

SB FINANCIAL GROUP INC.:

• $10 million to $15 million of convertible preferred shares

• Managed by Keefe Bruyette & Woods Inc.

• Registered

• Can be converted to common stock after five years

• Proceeds to redeem a portion of the company’s junior subordinated debentures underlying the trust preferred securities issued by the company’s RST I subsidiary and for general corporate purposes

• Defiance, Ohio-based community banking, mortgage banking, wealth management services company

• Nasdaq: SBFG

PLATFORM SPECIALTY PRODUCTS CORP.:

• Convertible securities as part of a funding package of cash, convertibles, debt and equity

• Proceeds to fund $3.51 billion acquisition of Arysta LifeScience Ltd., a Tokyo-based provider of agrochemical and biological products

• Barclays, Credit Suisse Securities (USA) LLC, Nomura Securities International LLC and UBS AG acted as M&A advisers and have committed financing for the acquisition

• Anticipated closing in first quarter 2015

• Miami-based specialty chemicals company

• NYSE: PAH


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.